An interventional study of Mediterranean diet and Very Low Ketogenic Diet in Steatohepatitis, Nonalcoholic, Steatosis of Liver and Cirrhosis, Liver, sponsored by University of Palermo. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-05.
Sponsored by University of Palermo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy — 21 open to participants now, 29 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Italy.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, this one is the 62nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 10 that started in 2024, is one of 31 with no phase, reaches primary completion later than 11 of the 28 other live ones, and was the 94th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →21 of the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Palermo · Sites in Italy
Ages 1–14
Eli Lilly and Company · Sites in Italy, United States, Argentina and 31 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Akero Therapeutics, Inc · Sites in Italy, United States, Argentina and 20 more countries
Ages 18–80
The Cleveland Clinic · Sites in Italy, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 24 · Phase 3 19 · Phase 4 2
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 150 across the 75 interventional studies, 136 across the 24 observational. Of the 55 that completed or were terminated, 25 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 99 have an industry lead sponsor. The 10 most frequent:
University of Palermo is the lead sponsor of 145 studies on the registry; 28 are open to participants now.
University of Palermo has 4 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Non-alcoholic Fatty Liver Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537466University of PalermoKetogenic Diet in MASLD-related cACLD | 2026-11 |
| NCT06888310Fondazione Policlinico Universitario Agostino Gemelli IRCCSOptimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease | 2026-12-01 |
| NCT06879236Fondazione Policlinico Universitario Agostino Gemelli IRCCSSecondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease | 2026-12-14 |
| NCT07644936Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisMolecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD. Therefore, the investigator propose a randomized controlled study that evaluates the impact of two dietary protocols -Mediterranean diet, and very low ketogenic diet- the MD and the VLCKD, in individuals with cACLD secondary to MASLD.
The rationale of the study stems from evidence that patients with "compensated advanced chronic liver disease" (cACLD) secondary to MASLD have higher risk of liver-related morbidity (liver decompensation, hepatocellular carcinoma) and mortality. However, todate the only approved drug by FDA in patients with MASH and F2-F3 fibrosis is Resmetirom, but it is still not available in clinical practice outside US. As a consequence, currently and in the future the first-line treatment of MASLD involved weight loss and lifestyle modification, such as physical exercise and dietary regimens based on calorie restriction. In this context the Mediterranean diet is considered the standard, but over the last decade, the Very low-carbohydrate ketogenic diets (VLCKD) has gained immense popularity for its short-term positive effects on weight loss, even if data on MASLD cACLD are lacking.
Therefore, considering recent evidence, the investigator hypothesize that VLCKD could represent a new therapeutic option in the management of patients with MASLD and cACLD. Specifically, the investigator propose a randomized controlled study that evaluates the 48 week impact of two dietary protocols, the MD and the VLCKD, in individuals with cACLD secondary to MASLD, with specific focus on weight loss >=10% and on liver-related (changes in liver stiffness by TE, MRE and MRI-PDFF, AST, ALT) and metabolic parameters (see section on outcomes) Here the investigators report the detailed proposed nutritional protocols
The Kalibra protocol consists of 3 stages:
WEIGHT LOSS: Ketogenic metabolism is activated by reduced carbohydrate intake. As an accessory phenomenon to lipolysis and the catabolism of fat reserves in adipose tissue, there is a physiological production of ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone), which represent a water-soluble and readily available energy source for many tissues in the body (brain, heart, and muscles). Continuous ketogenesis, in addition to providing adequate energy intake, is important to ensure the absence of hunger and a feeling of overall well-being throughout the weight loss period.
TRANSITION: gradual reintroduction of traditional foods. In this phase, the patient is reeducated to adopt a healthy and correct lifestyle in order to optimize and stabilize the results obtained in the attack phase.
MAINTENANCE: once the patient has achieved their overall goals, they embark on a long-term nutritional path following the LARN (Reference Intake Levels of Nutrients and Energy for the Italian population).
In the first phase, known as the classic ketogenic phase (21 days), the protocol involves replacing all meals with Kalibra products, accompanied by low-carbohydrate vegetables. It is essential to include supplementation with trace elements, minerals, and vitamins. The number of meals is determined based on the patient's height in centimeters (tab1).
During the period when following the Kalibra method, it is recommended to engage in physical activity for muscle toning of arms, legs, abdominals, and glutes for 20-30 minutes at least 3 times a week. A workout plan will be provided.
Table 1 height in centimeters \<160 160-170 170-180 >180 Man 3-4 meals 4 meals 4-5 meals 5 meals Woman 5 meals 5 meals 6 meals 6-7 meals Tab1 Number of meal replacements based on height. The second ketogenic phase, called the Mitigated Diet (21 days), involves reducing one Kalibra meal and the possibility of adding a portion of meat, fish, or eggs during one of the main meals, accompanied by low-carbohydrate vegetables. This allows for the maintenance of ketogenesis with consequent weight loss while also allowing the patient a reasonable level of social interaction.
The Transition Phase represents an extremely important phase as it allows for the stabilization of the achieved weight through a gradual and measured increase in daily caloric intake.
Each stage, each lasting 21 days, involves a caloric increase of approximately 150 kcal correlated with:
Once the 4 stages of the transition are completed, the patient will have finished their dietary journey and can then maintain the achieved results by daily application of a new lifestyle based on healthy and balanced nutrition, taking into account fundamental aspects of the Mediterranean diet.
Here the investigators report the detailed clinical and laboratory assessment:
Nutritional status will be assessed using the Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT), recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines for stratifying malnutrition risk in patients with liver diseases. Evaluation will include: Weight (Kg), height (cm), waist and hip circumference (cm), arm circumference (cm), triceps skinfold (using a caliper), thigh and suprapatellar root measurements. Body mass index (BMI) will be calculated based on weight in kilograms and height in meters.
Body composition will be assessed using bioimpedance analysis and muscle strength will be evaluated using a dynamometer. A walking test will be conducted, and the Liver Frailty Index will be calculated.
Weight and circumferences will be assessed at each visit. A comprehensive evaluation will be performed at the end of each phase.
A 12-hour overnight fasting blood sample will be drawn at screening and during follow-up visits determine serum levels of Hb, WBC, ALT, AST, ɣ-glutamyltransferase (ɣ-GT) , alkaline phosphatase, total and direct bilirubin, INR, albumin, total cholesterol, HDL and LDL-cholesterol, triglycerides, plasma glucose concentration, platelet count , NA/K and creatinine.
Here the investigators report the detailed liver instrumental assessment:
At baseline, all patients will undergo an ultrasound (US) examination to evaluate liver structure and the presence of signs of portal hypertension. Transient elastography will be performed using a FibroScan apparatus (Echosens, Paris , France) to measure liver stiffness and controlled attenuation parameter. The median value of 10 successful acquisitions, expressed in kilopascal (kPa), will be kept as representative of LSM. The investigator will consider 10 successful acquisitions with a success rate of at least 60% and with an interquartile range lower than 20% as representative measurements. During the same session, MRE and MRI-PDFF will be used as diagnostic tools for noninvasive quantitative assessment of steatosis and liver fibrosis; muscle mass will be also evaluated at L3 level. Transient elastography will be repeated every three months, US will be repeated every six months, and the MRE and MRI-PDFF will be performed at the end of the therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
Dietary Supplement: Mediterranean diet
The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
Dietary Supplement: Very Low Ketogenic Diet
This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
weight loss≥10% compared to the initial weight in individuals with cACLD secondary to MASLD
Weight in Kg
Time frame: 48 weeks
▪ changes in liver stiffness by Magnetic Resonance Elastography (MRE)
MRE in KPa
Time frame: 48 weeks
▪ changes in liver fat by Magnetic Resonance Imaging-proton density fat fraction (MRI-PDFF)
MRI-PDFF in %
Time frame: 48 weeks
▪ changes in liver stiffness by transient elastography
Liver Stiffness in KPa
Time frame: 48 weeks
▪ changes in liver fat by controlled attenuation parameter (CAP)
CAP in dB/m
Time frame: 48 weeks
▪ changes in Spleen stiffness by Magnetic Resonance Elastography (MRE)
Spleen Stiffness in KPa
Time frame: 48 weeks
▪ changes in Spleen stiffness by Transient Elastography
Spleen stiffness in KPa
Time frame: 48 weeks
▪ changes in AST serum levels
AST in IU
Time frame: 48 weeks
▪ changes in ALT serum levels
ALT in IU
Time frame: 48 weeks
▪ changes in GGT serum levels
GGT in IU
Time frame: 48 weeks
▪ changes in alcaline phosphatase serum levels
alcaline phosphatase in IU
Time frame: 48 weeks
▪ changes in albumin serum levels
albumin in g/L
Time frame: 48 weeks
▪ changes in INR serum levels
INR in IU
Time frame: 48 weeks
▪ changes in bilirubin serum levels
bilirubin in mg/dl
Time frame: 48 weeks
▪ changes in total, HDL and LDL cholesterol serum levels
total, HDL and LDL cholesterol in mg/dl
Time frame: 48 weeks
▪ changes in glucose serum levels
gluceos in mg/dl
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2024; primary completion for Nov 2026, 24 months later.
Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 24 months is close to that.
Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →